Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 13;20:7. doi: 10.1186/s12876-019-1130-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2020

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Survival analysis. Tacrolimus remarkably prolonged both WAT and SAT group survivals (p < 0.01, compared with WA and SA), but there was still significant difference between WAT and SAT p = 0.047). Compared to the SAT group, mean survival time was much longer than that in SATa group (p = 0.331). 28-day cumulative survival rates (85.7%) of WAT group were higher than SAT group (28.6%) (P = 0.019, log-rank test). The survival rate (51.7%) of SATa is higher than SAT group (P = 0.266, log-rank test). whole size allografrs (WA), small-for-size allograft (SA), whole size allografrs+Tac (WAT), small-for-size allograft+Tac (SAT), small-for-size allograft+Tac altered dose (SATa)